HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +4.8% ·
aandelenstroom +7.6% ·
netto nieuwe posities 0.0%
· formule
Brede accumulatie: stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 502.79K | $49.11M | n/a | n/a |
| Q2 2026 | 131 | -1 | 91.15M | $6.60B | +6 | −8 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | n/a | n/a |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | n/a | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | n/a | −1 |
| Q2 2024 | 14 | n/a | 8.14M | $426.06M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 12.86M | -2.6% | $943.17M | 0.0% | ▼ Trim | 2 | SEC ↗ ×19 |
| 2 | The Vanguard Group ✦ (passief) | 11.63M | -5.0% | $852.93M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passief) | 5.02M | -15.4% | $368.11M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 4 | Arrowstreet Capital ✦ | 3.29M | +29.5% | $241.34M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 2.65M | +160.2% | $194.38M | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Geode Capital Management ✦ (passief) | 2.43M | -0.1% | $178.34M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Morgan Stanley ✦ | 1.74M | n/a | $127.44M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 8 | JPMorgan Chase ✦ | 1.54M | n/a | $112.63M | 0.0% | n/c | 1 | SEC ↗ ×22 |
| 9 | Two Sigma Investments ✦ | 1.32M | +199.2% | $96.51M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.23M | +77.8% | $90.03M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Renaissance Technologies ✦ | 1.00M | +195.4% | $73.36M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 968.51K | +155.7% | $71.03M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 13 | Capital World Investors ✦ | 831.66K | +6.3% | $60.99M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 825.42K | -20.0% | $60.54M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | Goldman Sachs Group ✦ | 684.52K | n/a | $50.20M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 16 | Bridgewater Associates ✦ | 487.08K | Nieuw | $35.72M | 0.1% | New | 1 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 410.89K | +7.6% | $30.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Marshall Wace ✦ | 393.75K | +1.2% | $28.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 252.93K | +271.7% | $18.55M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 244.80K | -21.4% | $17.95M | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 21 | Wellington Management ✦ | 37.13K | -64.2% | $2.72M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | Fidelity (FMR) ✦ | 20.75K | -75.5% | $1.52M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $35.72M | 0.1% |
Verlaten
| Norges Bank | $45.03M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 630 houders, 119.44M aandelen, $7.40B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 200 aand · $22,102
Officer, Director · 11.90K aand · $1.31M
Officer, Director · 3.09K aand · $336,526
Officer, Director · 4.81K aand · $520,341
Officer, Director · 8.60K aand · $954,867
Officer, Director · 200 aand · $22,739
Officer, Director · 900 aand · $101,502
Officer, Director · 10.30K aand · $1.15M
Officer, Director · 1.78K aand · $197,245
Officer, Director · 9.92K aand · $1.09M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie